Recent Company News

• 05:02 PM ET Dec 23, 2025
  

  Ono Pharmaceutical downgraded to neutral from outperform at Mizuho (¥2205.0000, 0)

• 07:06 AM ET Dec 17, 2025
  

  Bristol Myers Squibb Canada announces CDA recommendation for OPDIVO plus YERVOY as first-line treatment for MSI-H/dMMR metastatic colorectal cancer ($54.23, 0.00)

• 05:14 PM ET Dec 16, 2025
  

  Malaysian NPRA approves Antengene's XPOVIO sNDA for treatment of adult patients with relapsed or refractory DLBCL (HK$4.00, 0.00)

• 04:25 PM ET Dec 08, 2025
  

  Ono Pharmaceutical initiated neutral at SBI Securities Japan (¥2120.5000, 0)

• 10:26 PM ET Dec 06, 2025
  

  Ono Pharmaceutical presents positive results from Phase 2a IMPRSSION study of sapablursen in patients with PV at ASH 2025 (¥2103.0000, 0)

• 10:56 PM ET Nov 26, 2025
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (121 total)

• 09:58 PM ET Nov 26, 2025
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (247 total)

• 10:32 PM ET Nov 25, 2025
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (93 total)

• 10:06 PM ET Nov 25, 2025
  

  StreetAccount Summary: Japan Stocks reaching new 52-week highs/lows (216 total)

• 11:08 PM ET Nov 24, 2025
  

  StreetAccount Summary: Asian stocks reaching new 52-week highs/lows (80 total)